Drawing for POLYNAUT

USPTO serial 88261248

POLYNAUT

Reviewed by CopyMark Law Group

Reg. 5987728Status 710
Filing date
Status date
Registration date
Feb 18, 2020
Examiner
WILSON, MARYNELLE WEST
Law office
TMO LAW OFFICE 113

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with POLYNAUT?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Ben Natter

Ben Natter HAUG PARTNERS LLP745 Fifth AvenueNew York, NY 10151UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Chemicals used in science; chemicals for encapsulating, microencapsulating and decapsulating other chemicals; chemicals for the protection, delivery, transport and triggered or controlled release of other chemicals; chemicals for encapsulating, microencapsulating and decapsulating biologically active ingredients including enzymes and cells; reagents and diagnostic preparations for scientific or medical research use, and clinical or medical laboratory use in oncology; targeted diagnostic preparations for scientific or medical research use, and clinical or medical laboratory use in oncologySECTION 8 - CANCELLED—
005Pharmaceutical preparations for the treatment and prevention of infectious, autoimmune, viral, metabolic, musculoskeletal, cardiovascular, genitourinary, central nervous system, endocrinological, immunological, obstetrical, gynaecological, oncological, respiratory, neurological, gastrointestinal, hormonal, dermatological and psychiatric diseases and disorders; reagents, diagnostics and therapeutic preparations for medical and veterinary use in oncology; therapeutic preparations for use in treating cancer in medical and veterinary patients; targeted medical and veterinary preparations for use in oncology; medical and veterinary preparations for use in chemotherapy and immunotherapy for the treatment and prevention of infectious, autoimmune, viral, metabolic, musculoskeletal, cardiovascular, genitourinary, central nervous system, endocrinological, immunological, obstetrical, gynaecological, oncological, respiratory, neurological, gastrointestinal, hormonal, dermatological and psychiatric diseases and disorders; medical and veterinary preparations for the delivery of compounds to the brain for the treatment and prevention of infectious, autoimmune, viral, metabolic, musculoskeletal, cardiovascular, genitourinary, central nervous system, endocrinological, immunological, obstetrical, gynaecological, oncological, respiratory, neurological, gastrointestinal, hormonal, dermatological and psychiatric diseases and disorders; medical and veterinary preparations for crossing the blood-brain barrier for the treatment and prevention of infectious, autoimmune, viral, metabolic, musculoskeletal, cardiovascular, genitourinary, central nervous system, endocrinological, immunological, obstetrical, gynaecological, oncological, respiratory, neurological, gastrointestinal, hormonal, dermatological and psychiatric diseases and disorders; medical and veterinary preparations for delivering reagents, diagnostics and therapeutics across the blood-brain barrier for the treatment and prevention of infectious, autoimmune, viral, metabolic, musculoskeletal, cardiovascular, genitourinary, central nervous system, endocrinological, immunological, obstetrical, gynaecological, oncological, respiratory, neurological, gastrointestinal, hormonal, dermatological and psychiatric diseases and disordersSECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 28, 2026C8..CANCELLED SEC. 8 (6-YR)—
Feb 18, 2025REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Jan 20, 2022TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jan 20, 2022ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 20, 2022REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Dec 30, 2020ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
May 6, 2020COC.CORRECTION UNDER SECTION 7 - PROCESSED—
May 5, 2020EROPTEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED—
May 4, 2020PRAMPOST REGISTRATION ACTION MAILED - SEC. 7—
Apr 27, 2020APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Mar 21, 2020ES7RTEAS SECTION 7 REQUEST RECEIVED—
Mar 20, 2020ES7RTEAS SECTION 7 REQUEST RECEIVED—
Feb 18, 2020R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Dec 3, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 3, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 13, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Oct 28, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 28, 2019XAECEXAMINER'S AMENDMENT ENTERED—
Oct 28, 2019GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Oct 28, 2019GNEAEXAMINERS AMENDMENT E-MAILED—
Oct 28, 2019CNEAEXAMINERS AMENDMENT -WRITTEN—
Oct 8, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 8, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 7, 2019ALIEASSIGNED TO LIE—
Oct 1, 2019TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 3, 2019GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 3, 2019GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 3, 2019CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 27, 2019DOCKASSIGNED TO EXAMINER—
Feb 7, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jan 17, 2019NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance